Research programme: seliciclib derivatives - Cyclacel
Latest Information Update: 26 Mar 2016
At a glance
- Originator Cyclacel Pharmaceuticals
- Class Purines
- Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 May 2009 Preclinical trials in Cancer in United Kingdom (PO)